SIMULTANEOUS DETERMINATION OF GUAIFENESIN AND EPHEDRINE HCl BINARY MIXTURE IN SYRUP DOSAGE FORMS AND HUMAN PLASMA BY USING RP-HPLC-DAD

Imamoglu, Esin; Tunca, Aysel Kucuk

doi:10.1080/10826076.2013.765459

Cited by 6 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In present work, an easy, fast, practical and economical HPLC method with reverse-phase DAD detector was developed for the quantitative analysis of guaifenesin active ingredient alone in a trade preparation (Expectorant syrup containing 200 mg/15 mL guaifenesin) or in human plasma as in vitro. This study is the continuation of previous work related to the quantity analysis of guaifenesin mixed with an another active ingredient (Efedrin HCl) in a trade preparation [23]. Furthermore, thanks to the method developed under the same chromatographic conditions with previous study, guaifenesin and sibutramin (internal standard) quantity analysis were carried out using less methanol in very short retention times in an economic and environmentally friendly way and very high recovery values obtained without any need for an extraction process.…”

Section: Introductionmentioning

confidence: 85%

Quantitation of Guaifenesin (Glyceryl Guaiacolate) in Syrup and Spiked Human Plasma using HPLC with Diode Array Detection

Tunca¹,

Aydogan²

2017

Asian J. Chem.

Self Cite

View full text Add to dashboard Cite

A new, simple and rapid reverse phase-high performance liquid chromatography-diode array detection (RP-HPLC-DAD) method has been developed using sibutramin (S) as internal standard for quantitative determination of guaifenesin (G) and validated both in syrup dosage forms and spiked human plasma samples. The analysis was carried out within 10 min on Inertsil C18 column using isocratic mobile phase consists of phosphate buffer and methanol with pH 3 (60:40, v/v) at a flow-rate of 1 mL min -1 and detection at 212 nm. The concentration-response relationship was linear over a concentration range of 10-100 µg mL -1 for guaifenesin. The developed liquid chromatographic method was successfully applied for the routine analysis of guaifenesin in a cough syrup and human plasma samples without liquid-liquid extraction for quality control purposes. After the method development, bioanalytical method validation was applied. For this purpose, all the validation parameters such as intra-day and inter-day precisions, accuracy, specificity, selectivity and recovery were determined. After the validation procedure, the results were evaluated statistically.

show abstract

Section: Introductionmentioning

confidence: 85%

Quantitation of Guaifenesin (Glyceryl Guaiacolate) in Syrup and Spiked Human Plasma using HPLC with Diode Array Detection

Tunca¹,

Aydogan²

2017

Asian J. Chem.

Self Cite

View full text Add to dashboard Cite

show abstract

Improving Robustness of Pharmaceutical Dosage form Sample Preparation Using Experimental Design and Process Understanding Tools

et al. 2020

View full text Add to dashboard Cite

Green highly sensitive and selective spectroscopic detection of guaifenesin in multiple dosage forms and spiked human plasma

Mikawy,

Magdy,

Mohamed

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Guaifenesin (GUA) is determined in dosage forms and plasma using two methods. The spectrofluorimetric technique relies on the measurement of native fluorescence intensity at 302 nm upon excitation wavelength “223 nm”. The method was validated according to ICH and FDA guidelines. A concentration range of 0.1–1.1 μg/mL was used, with limit of detection (LOD) and quantification (LOQ) values 0.03 and 0.08 µg/mL, respectively. This method was used to measure GUA in tablets and plasma, with %recovery of 100.44% ± 0.037 and 101.03% ± 0.751. Furthermore, multivariate chemometric-assisted spectrophotometric methods are used for the determination of GUA, paracetamol (PARA), oxomemazine (OXO), and sodium benzoate (SB) in their lab mixtures. The concentration ranges of 2.0–10.0, 4.0–16.0, 2.0–10.0, and 3.0–10.0 µg/mL for OXO, GUA, PARA, and SB; respectively, were used. LOD and LOQ were 0.33, 0.68, 0.28, and 0.29 µg/mL, and 1.00, 2.06, 0.84, and 0.87 µg/mL for PARA, GUA, OXO, and SB. For the suppository application, the partial least square (PLS) model was used with %recovery 98.49% ± 0.5, 98.51% ± 0.64, 100.21% ± 0.36 & 98.13% ± 0.51, although the multivariate curve resolution alternating least-squares (MCR-ALS) model was used with %recovery 101.39 ± 0.45, 99.19 ± 0.2, 100.24 ± 0.12, and 98.61 ± 0.32 for OXO, GUA, PARA, and SB. Analytical Eco-scale and Analytical Greenness Assessment were used to assess the greenness level of our techniques.

show abstract

SIMULTANEOUS DETERMINATION OF GUAIFENESIN AND EPHEDRINE HCl BINARY MIXTURE IN SYRUP DOSAGE FORMS AND HUMAN PLASMA BY USING RP-HPLC-DAD

Cited by 6 publications

References 7 publications

Quantitation of Guaifenesin (Glyceryl Guaiacolate) in Syrup and Spiked Human Plasma using HPLC with Diode Array Detection

Quantitation of Guaifenesin (Glyceryl Guaiacolate) in Syrup and Spiked Human Plasma using HPLC with Diode Array Detection

Improving Robustness of Pharmaceutical Dosage form Sample Preparation Using Experimental Design and Process Understanding Tools

Green highly sensitive and selective spectroscopic detection of guaifenesin in multiple dosage forms and spiked human plasma

Contact Info

Product

Resources

About